ALFA Finder| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 40.7 | 39.5 | 37.5 |
| Other income | 0.2 | 0.0 | 0.0 |
| Total income | 40.9 | 39.5 | 37.5 |
| Profit before exceptional items & tax | 5.1 | 5.0 | 3.5 |
| Profit before tax | 5.1 | 5.0 | 3.5 |
| Net profit | 3.8 | 3.7 | 2.6 |
| Operating margin | 12.5% | 12.7% | 9.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +46.20% |
|---|---|
| Net profit, quarter on quarter | +2.70% |
| Revenue, year on year | +8.50% |
| Operating profit, year on year | +40.00% |
| Operating profit, quarter on quarter | -2.00% |
BSE results filing, NSE: MACINTR. Figures extracted from the filing.
Astal Laboratories Ltd: key numbers
- Share price
- ₹63.24
- Market cap
- ₹267.0 Cr
- Revenue (annual)
- ₹156.0 Cr
- Net profit (annual)
- ₹8.12 Cr
- P/E (TTM)
- 27.4×Sector 47.0×
- Promoter holding
- 4.59%+0.06% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Astal Laboratories Ltd
All →Astal Laboratories Other Announcement
Astal Laboratories filed its Reg 32 statement for the quarter ended 30 September 2026, confirming no deviation in use of funds. The Rs 33.99 Lakh preferential issue proceeds were fully utilised as originally disclosed.
Astal Laboratories Board Meeting Date
Astal Laboratories will hold a board meeting on 13 November 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended September 2026. The trading window stays closed until 48 hours after the meeting.
Astal Laboratories Other Announcement
Astal Laboratories submitted the Regulation 74(5) certificate from its Registrar for the quarter ended September 30, 2026, confirming the dematerialization activities.
Astal Laboratories Other Announcement
Astal Laboratories' material subsidiary, Sriven Pharmachem India, appointed new Internal, Cost, and Secretarial Auditors. The appointments were approved during the subsidiary's board meeting on September 28, 2026.
Astal Laboratories Management Change
Astal Laboratories Limited has appointed Ms. Ambika Kedia as Company Secretary of its material wholly-owned subsidiary, Sriven Pharmachem India Private Limited. The appointment is effective from September 28, 2026.
Astal Laboratories Annual General Meeting
Astal Laboratories held its 33rd Annual General Meeting on September 29, 2026. Members transacted business regarding financial statements and the re-appointment of a director.